Home > Browse Issues > Vol.36 No.9
Several Questions Related to Adoptive Cellular Immunotherapy in Clinical Practice
Huang Hao, Zhang Zhenghan, Allen Edward Goldenthal, Luo Chenglin, Luo Xiaoling*
Clinical Center of Shenzhen Hornetcorn Biotechnology Co. Ltd., Shenzhen 515000, China
Abstract: During the past decade， adoptive cell therapy (ACT) has been quickly developed in our country as one of the most important compositions of tumor immunotherapy. However， its clinical efficacy remains controversial. ACT technology causes the attention of clinical physicians once again with the improvement of immune technique in recent years. We have made a simple review in this article including the process of ACT technology development and selection of cell type during the clinical application， determination of cell number， evaluation of curative effect and other issues.
CN
EN